Martingale Asset Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
RI
JT
Martingale Asset Management's PTCT Position: Q2 2026 in Review
Martingale Asset Management reduced its PTC Therapeutics (PTCT) stake by 2.3% in Q2 2026, selling an estimated $74.5K and leaving 44,475 shares worth $3.63M. The position accounts for 0.09% of the portfolio, ranked #244.
Martingale Asset Management first reported a position in PTCT in Q4 2020 and has held it in 17 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Martingale Asset Management held 44,475 shares of PTC Therapeutics worth $3.63M as of Q2 2026.
- Martingale Asset Management sold 1,032 PTC Therapeutics shares in Q2 2026, an estimated $74.5K.
- PTC Therapeutics made up 0.09% of Martingale Asset Management's portfolio in Q2 2026, its #244 holding.
- Martingale Asset Management first reported a position in PTC Therapeutics in Q4 2020 and has held it in 17 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.